Million M E, Mailliett P, Chen H, Bashiardes G, Boiziau J, Parker F, Commerçon A, Tocque B, Roques B P, Garbay C
Département de Pharmacochimie Moléculaire et Structurale, U266 INSERM-URA D 1500 CNRS, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France.
Anticancer Drug Des. 1996 Mar;11(2):129-53.
In order to design new potent inhibitors of the epidermal growth factor receptor (EGF-R) associated protein tyrosine kinase (PTK) activity as antitumor agents, several families of phenylhydroquinone derivatives were synthesized. Some of these compounds were shown to block PTK activity in vitro, but also efficiently to inhibit EGF-stimulated DNA synthesis in ER 22 cells (CCL 39 hamster fibroblasts transfected with EGF-R) with IC50 values in the range 1-10 microM. In some cases, a correlation between the two sets of data was observed, allowing structure-activity relationships to be established. However, inhibitors which had in vitro specificity with regard to other kinases were not specific in the cellular test. Similar effects on DNA synthesis were observed after stimulation by various activating agents, suggesting that our compounds may also act against other cellular targets involved in the EGF-dependent pathways leading to cell proliferation.
